Sugi Predict

Sugi Predict / Compounds / SCHEMBL12434384

SCHEMBL12434384

SCHEMBL12434384

CC(=O)CCCCCCCNC(=O)c1ccccc1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 2/20 0.73
▸ ALOX5 P09917 3/20 0.62
▸ HTT P42858 3/20 0.60
▸ TSHR P16473 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ NLRP1 Q9C000 1/20 0.60
▸ NAMPT P43490 1/20 0.58
▸ KDM4E B2RXH2 1/20 0.57
▸ HDAC7 Q8WUI4 1/20 0.52
▸ HDAC3 O15379 1/20 0.50
▸ HDAC1 Q13547 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ESRRG P62508 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13523839 1.00 NAAA (0.73) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL15887763 0.90 ALOX5 (0.79) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL823552 0.89 NAAA (0.84) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL14088979 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL6383063 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
Salcaprozic Acid SCHEMBL4586235 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL14088978 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL664024 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL2331916 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1
SCHEMBL13593340 0.86 NAAA (0.70) NAAAALOX5HTTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207409-A1 ORAL DELIVERY OF OLIGONUCLEOTIDES CIVI BIOPHARMA INC (US) 2024-06-27 — — US disclosed
WO-2023245061-A2 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUE Arrowhead Pharmaceuticals, Inc. (US) 2023-12-21 — — WO disclosed
US-20230338413-A1 ORAL DELIVERY OF HEPARINS GUANGZHOU DAZHOU BIOMEDICINE LTD. (CN) 2023-10-26 — — US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 — — US disclosed
US-20230234916-A1 N-[8-(2-HYDROXYBENZOYL)AMINO]POTASSIUM OCTANOATE CRYSTAL POLYMORPH, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sciwind Biosciences Co., Ltd. (CN) 2023-07-27 — — US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 — — US disclosed
WO-2022056273-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. (US) 2022-03-17 — — WO disclosed
US-9636406-B2 Method of treating cancer INTENSITY THERAPEUTICS, INC. (US) 2017-05-02 — — US disclosed
US-20160166697-A1 METHOD OF TREATING CANCER INTENSITY THERAPEUTICS, INC. 2016-06-16 — — US disclosed
US-9351997-B2 Method of treating cancer INTENSITY THERAPEUTICS, INC. (US) 2016-05-31 — — US disclosed
US-9345722-B2 Pharmaceutical formulations for the treatment of alzheimer's disease EMISPHERE TECHNOLOGIES, INC. (US) 2016-05-24 — — US disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 — — US disclosed
US-20140248211-A1 METHOD OF TREATING CANCER INTENSITY THERAPEUTICS, INC. (US) 2014-09-04 — — US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 — — US disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 — — US disclosed
US-20100004310-A1 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE EMISPHERE TECHNOLOGIES INC. (US) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 NAAA 1645/4885ALOX5 2377/4885HTT 1487/4885
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 NAAA 4405/4885ALOX5 2065/4885HTT 3614/4885
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 NAAA 1645/4885ALOX5 2377/4885HTT 1487/4885
US-20240207409-A1 ORAL DELIVERY OF OLIGONUCLEOTIDES RNGTT, RNMT, SRRT NAAA 3413/4885ALOX5 1678/4885HTT 933/4885
US-20230338413-A1 ORAL DELIVERY OF HEPARINS HPSE, SERPINC1, F2 NAAA 3754/4885ALOX5 2948/4885HTT 124/4885
US-20140248211-A1 METHOD OF TREATING CANCER PBK, GZMB, NPC1L1 NAAA 1268/4885ALOX5 1019/4885HTT 4127/4885
US-20230234916-A1 N-[8-(2-HYDROXYBENZOYL)AMINO]POTASSIUM OCTANOATE CRYSTAL POLYMORPH, AND PREPARATION METHOD THEREFOR AND USE THEREOF SLC10A2, SLC38A7, SLC7A1 NAAA 4152/4885ALOX5 1316/4885HTT 842/4885
US-20160166697-A1 METHOD OF TREATING CANCER PBK, GZMB, NPC1L1 NAAA 1268/4885ALOX5 1019/4885HTT 4127/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 NAAA 4848/4885ALOX5 4774/4885HTT 4208/4885
US-20100004310-A1 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, APP NAAA 382/4885ALOX5 2312/4885HTT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.